Trial Profile
S0916, A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 in Patients With Bone Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Plozalizumab (Primary)
- Indications Bone metastases; Solid tumours
- Focus Biomarker; Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2012 Planned end date changed from 1 Aug 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 17 Mar 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.